1 Report Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Nanomedicines Market Size Growth Rate by Type: 2017 VS 2021 VS 2028 1.2.2 Nanoparticles 1.2.3 Nanoshells 1.2.4 Nanotubes 1.2.5 Nanodevices 1.2.6 Others 1.3 Market by Application 1.3.1 Global Nanomedicines Market Share by Application: 2017 VS 2021 VS 2028 1.3.2 Hospitals 1.3.3 Clinics 1.3.4 Research Institute 1.4 Study Objectives 1.5 Years Considered 2 Global Growth Trends 2.1 Global Nanomedicines Market Perspective (2017-2028) 2.2 Nanomedicines Growth Trends by Region 2.2.1 Nanomedicines Market Size by Region: 2017 VS 2021 VS 2028 2.2.2 Nanomedicines Historic Market Size by Region (2017-2022) 2.2.3 Nanomedicines Forecasted Market Size by Region (2023-2028) 2.3 Nanomedicines Market Dynamics 2.3.1 Nanomedicines Industry Trends 2.3.2 Nanomedicines Market Drivers 2.3.3 Nanomedicines Market Challenges 2.3.4 Nanomedicines Market Restraints 3 Competition Landscape by Key Players 3.1 Global Top Nanomedicines Players by Revenue 3.1.1 Global Top Nanomedicines Players by Revenue (2017-2022) 3.1.2 Global Nanomedicines Revenue Market Share by Players (2017-2022) 3.2 Global Nanomedicines Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 3.3 Players Covered: Ranking by Nanomedicines Revenue 3.4 Global Nanomedicines Market Concentration Ratio 3.4.1 Global Nanomedicines Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by Nanomedicines Revenue in 2021 3.5 Nanomedicines Key Players Head office and Area Served 3.6 Key Players Nanomedicines Product Solution and Service 3.7 Date of Enter into Nanomedicines Market 3.8 Mergers & Acquisitions, Expansion Plans 4 Nanomedicines Breakdown Data by Type 4.1 Global Nanomedicines Historic Market Size by Type (2017-2022) 4.2 Global Nanomedicines Forecasted Market Size by Type (2023-2028) 5 Nanomedicines Breakdown Data by Application 5.1 Global Nanomedicines Historic Market Size by Application (2017-2022) 5.2 Global Nanomedicines Forecasted Market Size by Application (2023-2028) 6 North America 6.1 North America Nanomedicines Market Size (2017-2028) 6.2 North America Nanomedicines Market Size by Country (2017-2022) 6.3 North America Nanomedicines Market Size by Country (2023-2028) 6.4 United States 6.5 Canada 7 Europe 7.1 Europe Nanomedicines Market Size (2017-2028) 7.2 Europe Nanomedicines Market Size by Country (2017-2022) 7.3 Europe Nanomedicines Market Size by Country (2023-2028) 7.4 Germany 7.5 France 7.6 U.K. 7.7 Italy 7.8 Russia 7.9 Nordic Countries 8 Asia-Pacific 8.1 Asia-Pacific Nanomedicines Market Size (2017-2028) 8.2 Asia-Pacific Nanomedicines Market Size by Country (2017-2022) 8.3 Asia-Pacific Nanomedicines Market Size by Country (2023-2028) 8.4 China 8.5 Japan 8.6 South Korea 8.7 Southeast Asia 8.8 India 8.9 Australia 9 Latin America 9.1 Latin America Nanomedicines Market Size (2017-2028) 9.2 Latin America Nanomedicines Market Size by Country (2017-2022) 9.3 Latin America Nanomedicines Market Size by Country (2023-2028) 9.4 Mexico 9.5 Brazil 10 Middle East & Africa 10.1 Middle East & Africa Nanomedicines Market Size (2017-2028) 10.2 Middle East & Africa Nanomedicines Market Size by Country (2017-2022) 10.3 Middle East & Africa Nanomedicines Market Size by Country (2023-2028) 10.4 Turkey 10.5 Saudi Arabia 10.6 UAE 11 Key Players Profiles 11.1 Abbott 11.1.1 Abbott Company Detail 11.1.2 Abbott Business Overview 11.1.3 Abbott Nanomedicines Introduction 11.1.4 Abbott Revenue in Nanomedicines Business (2017-2022) 11.1.5 Abbott Recent Development 11.2 GE Healthcare 11.2.1 GE Healthcare Company Detail 11.2.2 GE Healthcare Business Overview 11.2.3 GE Healthcare Nanomedicines Introduction 11.2.4 GE Healthcare Revenue in Nanomedicines Business (2017-2022) 11.2.5 GE Healthcare Recent Development 11.3 Johnson & Johnson 11.3.1 Johnson & Johnson Company Detail 11.3.2 Johnson & Johnson Business Overview 11.3.3 Johnson & Johnson Nanomedicines Introduction 11.3.4 Johnson & Johnson Revenue in Nanomedicines Business (2017-2022) 11.3.5 Johnson & Johnson Recent Development 11.4 Merck 11.4.1 Merck Company Detail 11.4.2 Merck Business Overview 11.4.3 Merck Nanomedicines Introduction 11.4.4 Merck Revenue in Nanomedicines Business (2017-2022) 11.4.5 Merck Recent Development 11.5 Pfizer 11.5.1 Pfizer Company Detail 11.5.2 Pfizer Business Overview 11.5.3 Pfizer Nanomedicines Introduction 11.5.4 Pfizer Revenue in Nanomedicines Business (2017-2022) 11.5.5 Pfizer Recent Development 11.6 CombiMatrix 11.6.1 CombiMatrix Company Detail 11.6.2 CombiMatrix Business Overview 11.6.3 CombiMatrix Nanomedicines Introduction 11.6.4 CombiMatrix Revenue in Nanomedicines Business (2017-2022) 11.6.5 CombiMatrix Recent Development 11.7 Celgene 11.7.1 Celgene Company Detail 11.7.2 Celgene Business Overview 11.7.3 Celgene Nanomedicines Introduction 11.7.4 Celgene Revenue in Nanomedicines Business (2017-2022) 11.7.5 Celgene Recent Development 11.8 Mallinckrodt 11.8.1 Mallinckrodt Company Detail 11.8.2 Mallinckrodt Business Overview 11.8.3 Mallinckrodt Nanomedicines Introduction 11.8.4 Mallinckrodt Revenue in Nanomedicines Business (2017-2022) 11.8.5 Mallinckrodt Recent Development 11.9 Sigma-Tau Pharmaceuticals 11.9.1 Sigma-Tau Pharmaceuticals Company Detail 11.9.2 Sigma-Tau Pharmaceuticals Business Overview 11.9.3 Sigma-Tau Pharmaceuticals Nanomedicines Introduction 11.9.4 Sigma-Tau Pharmaceuticals Revenue in Nanomedicines Business (2017-2022) 11.9.5 Sigma-Tau Pharmaceuticals Recent Development 11.10 Teva Pharmaceutical 11.10.1 Teva Pharmaceutical Company Detail 11.10.2 Teva Pharmaceutical Business Overview 11.10.3 Teva Pharmaceutical Nanomedicines Introduction 11.10.4 Teva Pharmaceutical Revenue in Nanomedicines Business (2017-2022) 11.10.5 Teva Pharmaceutical Recent Development 11.11 Nanosphere 11.11.1 Nanosphere Company Detail 11.11.2 Nanosphere Business Overview 11.11.3 Nanosphere Nanomedicines Introduction 11.11.4 Nanosphere Revenue in Nanomedicines Business (2017-2022) 11.11.5 Nanosphere Recent Development 11.12 UCB SA 11.12.1 UCB SA Company Detail 11.12.2 UCB SA Business Overview 11.12.3 UCB SA Nanomedicines Introduction 11.12.4 UCB SA Revenue in Nanomedicines Business (2017-2022) 11.12.5 UCB SA Recent Development 12 Analyst's Viewpoints/Conclusions 13 Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.2 Data Source 13.2 Disclaimer 13.3 Author Details

List of Tables Table 1. Global Nanomedicines Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028 Table 2. Key Players of Nanoparticles Table 3. Key Players of Nanoshells Table 4. Key Players of Nanotubes Table 5. Key Players of Nanodevices Table 6. Key Players of Others Table 7. Global Nanomedicines Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028 Table 8. Global Nanomedicines Market Size by Region (US$ Million): 2017 VS 2021 VS 2028 Table 9. Global Nanomedicines Market Size by Region (2017-2022) & (US$ Million) Table 10. Global Nanomedicines Market Share by Region (2017-2022) Table 11. Global Nanomedicines Forecasted Market Size by Region (2023-2028) & (US$ Million) Table 12. Global Nanomedicines Market Share by Region (2023-2028) Table 13. Nanomedicines Market Trends Table 14. Nanomedicines Market Drivers Table 15. Nanomedicines Market Challenges Table 16. Nanomedicines Market Restraints Table 17. Global Nanomedicines Revenue by Players (2017-2022) & (US$ Million) Table 18. Global Nanomedicines Market Share by Players (2017-2022) Table 19. Global Top Nanomedicines Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Nanomedicines as of 2021) Table 20. Ranking of Global Top Nanomedicines Companies by Revenue (US$ Million) in 2021 Table 21. Global 5 Largest Players Market Share by Nanomedicines Revenue (CR5 and HHI) & (2017-2022) Table 22. Key Players Headquarters and Area Served Table 23. Key Players Nanomedicines Product Solution and Service Table 24. Date of Enter into Nanomedicines Market Table 25. Mergers & Acquisitions, Expansion Plans Table 26. Global Nanomedicines Market Size by Type (2017-2022) & (US$ Million) Table 27. Global Nanomedicines Revenue Market Share by Type (2017-2022) Table 28. Global Nanomedicines Forecasted Market Size by Type (2023-2028) & (US$ Million) Table 29. Global Nanomedicines Revenue Market Share by Type (2023-2028) Table 30. Global Nanomedicines Market Size by Application (2017-2022) & (US$ Million) Table 31. Global Nanomedicines Revenue Market Share by Application (2017-2022) Table 32. Global Nanomedicines Forecasted Market Size by Application (2023-2028) & (US$ Million) Table 33. Global Nanomedicines Revenue Market Share by Application (2023-2028) Table 34. North America Nanomedicines Market Size by Country (2017-2022) & (US$ Million) Table 35. North America Nanomedicines Market Size by Country (2023-2028) & (US$ Million) Table 36. Europe Nanomedicines Market Size by Country (2017-2022) & (US$ Million) Table 37. Europe Nanomedicines Market Size by Country (2023-2028) & (US$ Million) Table 38. Asia-Pacific Nanomedicines Market Size by Region (2017-2022) & (US$ Million) Table 39. Asia-Pacific Nanomedicines Market Size by Region (2023-2028) & (US$ Million) Table 40. Latin America Nanomedicines Market Size by Country (2017-2022) & (US$ Million) Table 41. Latin America Nanomedicines Market Size by Country (2023-2028) & (US$ Million) Table 42. Middle East & Africa Nanomedicines Market Size by Country (2017-2022) & (US$ Million) Table 43. Middle East & Africa Nanomedicines Market Size by Country (2023-2028) & (US$ Million) Table 44. Abbott Company Detail Table 45. Abbott Business Overview Table 46. Abbott Nanomedicines Product Table 47. Abbott Revenue in Nanomedicines Business (2017-2022) & (US$ Million) Table 48. Abbott Recent Development Table 49. GE Healthcare Company Detail Table 50. GE Healthcare Business Overview Table 51. GE Healthcare Nanomedicines Product Table 52. GE Healthcare Revenue in Nanomedicines Business (2017-2022) & (US$ Million) Table 53. GE Healthcare Recent Development Table 54. Johnson & Johnson Company Detail Table 55. Johnson & Johnson Business Overview Table 56. Johnson & Johnson Nanomedicines Product Table 57. Johnson & Johnson Revenue in Nanomedicines Business (2017-2022) & (US$ Million) Table 58. Johnson & Johnson Recent Development Table 59. Merck Company Detail Table 60. Merck Business Overview Table 61. Merck Nanomedicines Product Table 62. Merck Revenue in Nanomedicines Business (2017-2022) & (US$ Million) Table 63. Merck Recent Development Table 64. Pfizer Company Detail Table 65. Pfizer Business Overview Table 66. Pfizer Nanomedicines Product Table 67. Pfizer Revenue in Nanomedicines Business (2017-2022) & (US$ Million) Table 68. Pfizer Recent Development Table 69. CombiMatrix Company Detail Table 70. CombiMatrix Business Overview Table 71. CombiMatrix Nanomedicines Product Table 72. CombiMatrix Revenue in Nanomedicines Business (2017-2022) & (US$ Million) Table 73. CombiMatrix Recent Development Table 74. Celgene Company Detail Table 75. Celgene Business Overview Table 76. Celgene Nanomedicines Product Table 77. Celgene Revenue in Nanomedicines Business (2017-2022) & (US$ Million) Table 78. Celgene Recent Development Table 79. Mallinckrodt Company Detail Table 80. Mallinckrodt Business Overview Table 81. Mallinckrodt Nanomedicines Product Table 82. Mallinckrodt Revenue in Nanomedicines Business (2017-2022) & (US$ Million) Table 83. Mallinckrodt Recent Development Table 84. Sigma-Tau Pharmaceuticals Company Detail Table 85. Sigma-Tau Pharmaceuticals Business Overview Table 86. Sigma-Tau Pharmaceuticals Nanomedicines Product Table 87. Sigma-Tau Pharmaceuticals Revenue in Nanomedicines Business (2017-2022) & (US$ Million) Table 88. Sigma-Tau Pharmaceuticals Recent Development Table 89. Teva Pharmaceutical Company Detail Table 90. Teva Pharmaceutical Business Overview Table 91. Teva Pharmaceutical Nanomedicines Product Table 92. Teva Pharmaceutical Revenue in Nanomedicines Business (2017-2022) & (US$ Million) Table 93. Teva Pharmaceutical Recent Development Table 94. Nanosphere Company Detail Table 95. Nanosphere Business Overview Table 96. Nanosphere NanomedicinesProduct Table 97. Nanosphere Revenue in Nanomedicines Business (2017-2022) & (US$ Million) Table 98. Nanosphere Recent Development Table 99. UCB SA Company Detail Table 100. UCB SA Business Overview Table 101. UCB SA NanomedicinesProduct Table 102. UCB SA Revenue in Nanomedicines Business (2017-2022) & (US$ Million) Table 103. UCB SA Recent Development Table 104. Research Programs/Design for This Report Table 105. Key Data Information from Secondary Sources Table 106. Key Data Information from Primary Sources List of Figures Figure 1. Global Nanomedicines Market Share by Type: 2021 VS 2028 Figure 2. Nanoparticles Features Figure 3. Nanoshells Features Figure 4. Nanotubes Features Figure 5. Nanodevices Features Figure 6. Others Features Figure 7. Global Nanomedicines Market Share by Application in 2021 & 2028 Figure 8. Hospitals Case Studies Figure 9. Clinics Case Studies Figure 10. Research Institute Case Studies Figure 11. Nanomedicines Report Years Considered Figure 12. Global Nanomedicines Market Size (US$ Million), Year-over-Year: 2017-2028 Figure 13. Global Nanomedicines Market Size, (US$ Million), 2017 VS 2021 VS 2028 Figure 14. Global Nanomedicines Market Share by Region: 2021 VS 2028 Figure 15. Global Nanomedicines Market Share by Players in 2021 Figure 16. Global Top Nanomedicines Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Nanomedicines as of 2021) Figure 17. The Top 10 and 5 Players Market Share by Nanomedicines Revenue in 2021 Figure 18. North America Nanomedicines Market Size YoY Growth (2017-2028) & (US$ Million) Figure 19. North America Nanomedicines Market Share by Country (2017-2028) Figure 20. United States Nanomedicines Market Size YoY Growth (2017-2028) & (US$ Million) Figure 21. Canada Nanomedicines Market Size YoY Growth (2017-2028) & (US$ Million) Figure 22. Europe Nanomedicines Market Size YoY Growth (2017-2028) & (US$ Million) Figure 23. Europe Nanomedicines Market Share by Country (2017-2028) Figure 24. Germany Nanomedicines Market Size YoY Growth (2017-2028) & (US$ Million) Figure 25. France Nanomedicines Market Size YoY Growth (2017-2028) & (US$ Million) Figure 26. U.K. Nanomedicines Market Size YoY Growth (2017-2028) & (US$ Million) Figure 27. Italy Nanomedicines Market Size YoY Growth (2017-2028) & (US$ Million) Figure 28. Russia Nanomedicines Market Size YoY Growth (2017-2028) & (US$ Million) Figure 29. Nordic Countries Nanomedicines Market Size YoY Growth (2017-2028) & (US$ Million) Figure 30. Asia-Pacific Nanomedicines Market Size YoY Growth (2017-2028) & (US$ Million) Figure 31. Asia-Pacific Nanomedicines Market Share by Region (2017-2028) Figure 32. China Nanomedicines Market Size YoY Growth (2017-2028) & (US$ Million) Figure 33. Japan Nanomedicines Market Size YoY Growth (2017-2028) & (US$ Million) Figure 34. South Korea Nanomedicines Market Size YoY Growth (2017-2028) & (US$ Million) Figure 35. Southeast Asia Nanomedicines Market Size YoY Growth (2017-2028) & (US$ Million) Figure 36. India Nanomedicines Market Size YoY Growth (2017-2028) & (US$ Million) Figure 37. Australia Nanomedicines Market Size YoY Growth (2017-2028) & (US$ Million) Figure 38. Latin America Nanomedicines Market Size YoY Growth (2017-2028) & (US$ Million) Figure 39. Latin America Nanomedicines Market Share by Country (2017-2028) Figure 40. Mexico Nanomedicines Market Size YoY Growth (2017-2028) & (US$ Million) Figure 41. Brazil Nanomedicines Market Size YoY Growth (2017-2028) & (US$ Million) Figure 42. Middle East & Africa Nanomedicines Market Size YoY Growth (2017-2028) & (US$ Million) Figure 43. Middle East & Africa Nanomedicines Market Share by Country (2017-2028) Figure 44. Turkey Nanomedicines Market Size YoY Growth (2017-2028) & (US$ Million) Figure 45. Saudi Arabia Nanomedicines Market Size YoY Growth (2017-2028) & (US$ Million) Figure 46. Abbott Revenue Growth Rate in Nanomedicines Business (2017-2022) Figure 47. GE Healthcare Revenue Growth Rate in Nanomedicines Business (2017-2022) Figure 48. Johnson & Johnson Revenue Growth Rate in Nanomedicines Business (2017-2022) Figure 49. Merck Revenue Growth Rate in Nanomedicines Business (2017-2022) Figure 50. Pfizer Revenue Growth Rate in Nanomedicines Business (2017-2022) Figure 51. CombiMatrix Revenue Growth Rate in Nanomedicines Business (2017-2022) Figure 52. Celgene Revenue Growth Rate in Nanomedicines Business (2017-2022) Figure 53. Mallinckrodt Revenue Growth Rate in Nanomedicines Business (2017-2022) Figure 54. Sigma-Tau Pharmaceuticals Revenue Growth Rate in Nanomedicines Business (2017-2022) Figure 55. Teva Pharmaceutical Revenue Growth Rate in Nanomedicines Business (2017-2022) Figure 56. Nanosphere Revenue Growth Rate in Nanomedicines Business (2017-2022) Figure 57. UCB SA Revenue Growth Rate in Nanomedicines Business (2017-2022) Figure 58. Bottom-up and Top-down Approaches for This Report Figure 59. Data Triangulation Figure 60. Key Executives Interviewed

Abbott GE Healthcare Johnson & Johnson Merck Pfizer CombiMatrix Celgene Mallinckrodt Sigma-Tau Pharmaceuticals Teva Pharmaceutical Nanosphere UCB SA